Public data shows that among adults aged 20-79 in the world, there are already 463 million patients with type 2 diabetes (T2DM), and the number of diabetes patients in China has increased to 140 million. With the current trend of incidence, the global adult T2DM patients will be Over 700 million, with a growth rate of 51%. At present, the incidence of diabetes in China is 12.8%, with 1 in 8 Chinese people; the population with prediabetes accounts for 35.2%, and approximately 1 in 3 people is in prediabetes. In recent years, although many hypoglycemic drugs with different mechanisms of action have been put on the market, the patient’s overall blood glucose compliance rate is still less than 50%. Nowadays, China Medical’s dozaglifledin has been approved for production, and dozaglifled The damaged glucokinase (GK) in the patient's body enables the patient to restore its own physiological function of regulating glucose. Glucokinase (GK) is a blood glucose sensor in the human body and plays a central role in maintaining the steady state of human blood sugar. Or it will have the potential to fundamentally solve the instability of blood sugar in diabetic patients.